Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.

Heterozygous peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient (PPARgamma(+/-)) mice were protected from high-fat diet-induced insulin resistance. To determine the impact of systemic reduction of PPAR-gamma activity on beta-cell function, we investigated insulin secretion in PPARgamma(+/-) mice on a high-fat diet. Glucose-induced insulin secretion in PPARgamma(+/-) mice was impaired in vitro. The tissue triglyceride (TG) content of the white adipose tissue, skeletal muscle, and liver was decreased in PPARgamma(+/-) mice, but it was unexpectedly increased in the islets, and the increased TG content in the islets was associated with decreased glucose oxidation. Administration of a PPAR-gamma agonist, pioglitazone, reduced the islet TG content in PPARgamma(+/-) mice on a high-fat diet and ameliorated the impaired insulin secretion in vitro. Our results demonstrate that PPAR-gamma protects islets from lipotoxicity by regulating TG partitioning among tissues and that a PPAR-gamma agonist can restore impaired insulin secretion under conditions of islet fat accumulation.

[1]  J. H. Johnson,et al.  Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. , 1995, The Journal of biological chemistry.

[2]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[3]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[4]  R. Vigneri,et al.  Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. , 2000, Diabetes.

[5]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[6]  Yun-ping Zhou,et al.  Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. , 1994, The Journal of clinical investigation.

[7]  T. Kadowaki,et al.  The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes , 2000 .

[8]  M. Prentki,et al.  Long-term exposure of beta-INS cells to high glucose concentrations increases anaplerosis, lipogenesis, and lipogenic gene expression. , 1998, Diabetes.

[9]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[10]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[11]  H. Häring,et al.  The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects , 1999, Diabetologia.

[12]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[13]  H. Kasai,et al.  Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. , 1999, Science.

[14]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[15]  M. Kasuga,et al.  The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. , 2001, Diabetes.

[16]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[17]  J. McGarry,et al.  Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. , 1996, The Journal of clinical investigation.

[18]  B. Spiegelman,et al.  Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. , 2003, Molecular and cellular biology.

[19]  L. Hamann,et al.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.

[20]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .

[21]  E Moser,et al.  Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. , 1999, Diabetes.

[22]  M. Stumvoll,et al.  Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator--activated receptor-gamma2 gene. , 2001, Diabetes.

[23]  Y. Matsuzawa,et al.  Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase , 1999, Nature Genetics.

[24]  Yun-ping Zhou,et al.  Inhibitory effects of fatty acids on glucose-regulated B-cell function: association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolism. , 1996, Metabolism: clinical and experimental.

[25]  S. Aizawa,et al.  Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. , 2000, Diabetes.

[26]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[27]  F. Gonzalez.  Recent update on the PPARα-null mouse , 1997 .

[28]  B. Spiegelman,et al.  Targeted Elimination of Peroxisome Proliferator-Activated Receptor γ in β Cells Leads to Abnormalities in Islet Mass without Compromising Glucose Homeostasis , 2003, Molecular and Cellular Biology.

[29]  Y. Yazaki,et al.  A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. , 1998, Diabetes.

[30]  J. Auwerx.  PPARγ, the ultimate thrifty gene , 1999, Diabetologia.

[31]  R. Unger,et al.  Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats* , 1998, The Journal of Biological Chemistry.

[32]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[33]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[34]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[35]  V. Poitout,et al.  Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. , 2001, Diabetes.

[36]  J. McGarry,et al.  Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. , 1998, Diabetes.

[37]  B. Spiegelman,et al.  Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.

[38]  P. J. Randle,et al.  The glucose-fatty-acid cycle. , 1963, Lancet.

[39]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[41]  H. Mulder,et al.  Biochemical Mechanism of Lipid-induced Impairment of Glucose-stimulated Insulin Secretion and Reversal with a Malate Analogue* , 2004, Journal of Biological Chemistry.

[42]  R. Unger,et al.  Increased Lipogenic Capacity of the Islets of Obese Rats: A Role in the Pathogenesis of NIDDM , 1997, Diabetes.

[43]  M. Lane,et al.  High fat diet-induced hyperglycemia: prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[45]  G. Lienhard,et al.  Impact of Genetic Background and Ablation of Insulin Receptor Substrate (IRS)-3 on IRS-2 Knock-out Mice* , 2003, The Journal of Biological Chemistry.

[46]  U. Boggi,et al.  Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. , 2004, American journal of physiology. Endocrinology and metabolism.

[47]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[48]  Y. Terauchi,et al.  The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.